Article thumbnail

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

By Robert G Moses

Abstract

Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle advice plus metformin is commonly recommended initially to manage hyperglycemia and to minimize the risk of vascular complications. However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet®; Novo Nordisk, Bagsværd, Denmark) has been approved for use in the USA. This FDC is a rational second-line therapy given the complementary mechanisms of action of the components. Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3047998
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1999). A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care.
  2. (2008). Achieving glycosylated haemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clin Ther.
  3. (2002). Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther.
  4. American Diabetes Association. Standards of medical care
  5. (1998). Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med.
  6. (2003). Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther.
  7. (1990). Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes.
  8. Differences in risk of cardiovascular death according to type of oral glucose-lowering therapy in patients with diabetes: a nationwide study.
  9. (1999). Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care.
  10. et al; on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
  11. (2007). Federation. Guideline for management of postmeal glucose. Brussels: International Diabetes Federation,
  12. Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin. Clin Drug Invest.
  13. (1996). Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.
  14. (2003). for the repaglinide vs nateglinide metformin combination study group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care.
  15. (2009). for the repaglinide/ metformin fixed-dose combination study group. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycemic control. Diab Obes Metab.
  16. (2003). Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab.
  17. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care.
  18. (2007). Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev.
  19. (2005). Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev.
  20. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
  21. (1988). Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med.
  22. (2009). Package insert for Glucophage® (metformin hydrochloride) tablets and Glucophage® XR (metformin hydrochloride extended-release) tablets
  23. (2001). Patient perceptions of prandial oral therapy for type 2 diabetes. Diabetes Educ.
  24. (2008). Prescribing information for PrandiMet (repaglinide and metformin HCl) tablets,
  25. (1998). Repaglinide – prandial glucose regulator: a new class of oral antidiabetic drug. Diabet Med.
  26. (1999). Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract.
  27. (2006). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev.
  28. Single-dose pharmacokinetics of a repaglinide/metformin fixed-dose combination tablet in fasted and fed conditions.
  29. (2009). Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract.
  30. (2007). Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med.
  31. (2004). The combination and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med.
  32. (2009). W; for the repaglinide/ metformin fixed-dose combination study group. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycemic control comparable to rosiglitazone/metformin tablet. Diab Obes Metab.